Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
0.6325 USD -1.96% Intraday chart for Traws Pharma, Inc. -1.57% -15.17%
May. 07 Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy CI
Apr. 04 North American Morning Briefing : Focus Turns to -2- DJ

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
TRAWS PHARMA, INC. Stock Traws Pharma, Inc.
-15.17% 13.6M -
MODERNA, INC. Stock Moderna, Inc.
+64.92% 62.59B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.85% 41.18B
B
LONZA GROUP AG Stock Lonza Group AG
+44.76% 40.29B
A
CELLTRION, INC. Stock Celltrion, Inc.
-8.93% 27.9B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.05% 26.21B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.96% 19.09B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.21% 13.08B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.74% 12.26B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.42% 12.05B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. Ratings Traws Pharma, Inc.